Cocrystal Pharma Inc (COCP)
1.77
+0.01
(+0.57%)
USD |
NASDAQ |
Nov 13, 16:00
1.77
0.00 (0.00%)
After-Hours: 20:00
Cocrystal Pharma Research and Development Expense (Quarterly): 4.308M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 4.308M |
| March 31, 2024 | 2.95M |
| December 31, 2023 | 4.267M |
| September 30, 2023 | 4.194M |
| June 30, 2023 | 2.801M |
| March 31, 2023 | 3.907M |
| December 31, 2022 | 3.287M |
| September 30, 2022 | 3.872M |
| June 30, 2022 | 2.361M |
| March 31, 2022 | 2.872M |
| December 31, 2021 | 2.733M |
| September 30, 2021 | 2.105M |
| June 30, 2021 | 2.557M |
| March 31, 2021 | 1.577M |
| December 31, 2020 | 0.698M |
| September 30, 2020 | 2.077M |
| June 30, 2020 | 1.976M |
| March 31, 2020 | 1.283M |
| December 31, 2019 | 0.958M |
| September 30, 2019 | 1.077M |
| June 30, 2019 | 1.091M |
| March 31, 2019 | 0.878M |
| December 31, 2018 | 1.203M |
| September 30, 2018 | 1.467M |
| June 30, 2018 | 1.119M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.877M |
| December 31, 2017 | 1.104M |
| September 30, 2017 | 1.393M |
| June 30, 2017 | 1.255M |
| March 31, 2017 | 2.071M |
| December 31, 2016 | 93.88M |
| September 30, 2016 | 2.093M |
| June 30, 2016 | 2.368M |
| March 31, 2016 | 3.342M |
| December 31, 2015 | 41.51M |
| September 30, 2015 | 2.177M |
| June 30, 2015 | 1.946M |
| March 31, 2015 | 1.56M |
| December 31, 2014 | 1.349M |
| September 30, 2014 | 0.866M |
| June 30, 2014 | 0.888M |
| March 31, 2014 | 0.967M |
| December 31, 2013 | 0.926M |
| September 30, 2013 | 0.95M |
| June 30, 2013 | 0.98M |
| March 31, 2013 | 1.005M |
| December 31, 2012 | -0.0947M |
| September 30, 2012 | 0.1559M |
| June 30, 2012 | 0.2065M |
| March 31, 2012 | 0.2216M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.698M
Minimum
Dec 2020
4.308M
Maximum
Jun 2024
2.673M
Average
2.733M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 9.275M |
| Alaunos Therapeutics Inc | 0.18M |
| Oragenics Inc | 0.9068M |
| Cara Therapeutics Inc | 9.308M |
| Jaguar Health Inc | 3.653M |